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ABSTRACT 
Influenza is an infectious disease that represents an important public health burden, with high 
impact on the global morbidity, mortality and economy. The poor protection and the need of 
annual updating of the anti-influenza vaccine, added to the rapid emergence of viral strains 
resistant to current therapy make the need for antiviral drugs with novel mechanisms of action 
compelling. In this regard, the viral RNA polymerase is an attractive target that allows the design 
of selective compounds with reduced risk of resistance. In previous studies we showed that the 
inhibition of the polymerase acidic protein-basic protein 1 (PA-PB1) interaction is a promising 
strategy for the development of anti-influenza agents. Starting from the previously identified 3-
cyano-4,6-diphenyl-pyridines, we chemically modified this scaffold, and explored its structure-
activity relationships. Non-cytotoxic compounds with both the ability of disrupting the PA-PB1 
interaction and antiviral activity were identified and their mechanism of target binding was 
clarified with molecular modelling simulations.  
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INTRODUCTION 
Despite the efforts in antiviral research, influenza (Flu) is an infectious disease that still 
represents an important public health burden affecting 5-10% of the World’s population, 
resulting in 3-5 million severe cases and in 250-500 thousands deaths each year.1 It is caused by 
the ribonucleic acid (RNA) viruses of the Orthomyxoviridae family and they are classified in A, 
B and C according to their antigenic differences.2-4 Among these, influenza A virus (FluA) 
infects a variety of animals as well as humans. Hemagglutinin (HA) and neuraminidase (NA) are 
the two major viral antigenic glycoproteins and the 18 HA (H1-H18) and 11 NA (N1-N11) 
identified in FluA virus result in the generation of distinct viral subtypes.5 Some of them are 
responsible for severe upper respiratory diseases in humans that occur in both seasonal 
epidemics and sporadic pandemics associated with high morbidity and mortality. Millions of 
deaths were recorded in the most important pandemics of the last Century.6,7 In chronological 
order, these were: the Spanish Flu (H1N1 strain, in 1918),8,9 the Asian Flu (H2N2 strain, in 
1957),9 the Hong Kong Flu (H3N2 strain, in 1968)9 and the “swine” Flu (H1N1 strain, in 
2009).10 Recently, the zoonotic infection caused by the “avian” FluA subtype H7N9 registered a 
fatality rate of 25% of the confirmed cases. In this outbreak, it was proven that most of the 
patients were directly infected from poultry, although the existence of limited human-to-human 
spread could not be excluded. However, the possibility of sustained acquisition of human-to-
human transmission capabilities by this pathogen could result in a devastating worldwide health 
problem, raising much concern for its pandemic potential.11  
Re-assortments of the genetic material between different strains allow the virus to avoid host 
detection systems and the emergence of the extremely aggressive viruses responsible for the 
pandemics. These, antigenic drift in particular, are complicating factors hampering the 
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development of an effective and universal anti-Flu vaccine and, thus, the development of anti-
influenza drugs is essential for the fight of future Flu outbreaks.12,13 Clinical therapy relies only 
on two classes of drugs that inhibit either the M2 ion channel (amantadine and rimantadine) or 
NA (e.g. oseltamivir and zanamivir).14,15 M2 ion channel inhibitors were the first anti-influenza 
drugs approved. However, they are no longer recommended due to their serious side effects on 
the Central Nervous System (CNS) and the very rapid emergence of drug-resistant influenza 
strains.14-16 Furthermore, drug-resistant FluA viruses are also emerging for the current first line 
therapy (NA inhibitors), making the discovery of novel antiviral strategies essential.14,15,17-18  
A new molecular target that was identified in the last few years is FluA RNA-dependent RNA 
polymerase (RdRp), a protein complex essential for the viral replication and pathogenesis. 
Indeed, it is responsible for viral RNA replication and an endonuclease activity for the “cap-
snatching”, which is necessary for both transcription initiation and translation.19 Importantly, 
FluA RdRp is significantly different from human polymerases and it is highly conserved, 
facilitating the design of selective compounds with reduced probability of virus resistance 
development. RdRp is a complex of three virus-encoded subunits: the polymerase acidic protein 
(PA), the polymerase basic protein 1 (PB1) and the polymerase basic protein (PB2). Only the 
correct assembly of the three subunits allows the correct functioning of the enzyme.19-23 Thus, an 
attractive mechanism of FluA RdRp inhibition is the disruption of the PA-PB1 protein-protein 
interaction. This is a very promising strategy for anti-influenza drug discovery, as demonstrated 
by the emergence of protein-protein interaction (PPI) small-molecule inhibitors in recent 
years.14,15,24-36 Among these, a hit compound disrupting the PA-PB1 interaction was identified 
through a high-throughput docking as a potential FluA polymerase inhibitor and from this 
encouraging result a small library of purchased analogues was evaluated. With IC50 values in the 
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micromolar range, the activity related to the 3-cyano-4,6-diphenyl-pyridine scaffold was 
confirmed as being responsible for the disruption of the PA-PB1 complex through the interaction 
of these molecules with the C-terminal domain of PA, mimicking the hydrophilic N-terminal 
portion of PB1 (residues 1-4).35 In order to obtain a better understanding of the structure-activity 
relationship (SAR) of this promising class of compounds and aiming the improvement of their 
activity, a hit optimization process was performed in the study presented here. 
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RESULTS AND DISCUSSION 
Hit exploration.  
Starting from a simplified structure (compound 1) of the novel class of inhibitors identified in 
the previous virtual screening campaign,35 a series of analogues was designed for a better 
understanding of the underlying structure-activity relationships. The 3-cyano-4,6-diphenyl-
pyridine scaffold was systematically modified by either removing or replacing molecule 
portions. Furthermore, attempts to increase compound solubility (e.g. 2), to address the 
possibility of a covalent interaction between the protein and the thioether (e.g. 5 and 6) and to 
increase the synthetic feasibility (e.g. 14 and 15) were considered. All the synthesized 
compounds can be found in Table 1.  
 
Chemistry. 
Due to the removing and replacing strategy adopted in the design of the molecules, several 
synthetic routes were applied. However, 2-chloro-4,6-diphenylnicotinonitrile (16) was used as a 
common precursor for the synthesis of several compounds (1, 3-8, and 10), as shown in Scheme 
1. Of these, 1, 3, 4, 7 and 8 were obtained by nucleophilic aromatic substitution using the 
appropriate nucleophile (compounds 17a-e). Reaction conditions differed according to the 
reactant properties and in several cases temperature control was important in order to avoid the 
formation of a highly fluorescent ring-closed side product. Extensive analysis was performed to 
confirm the regiochemistry of these reactions. An efficient Heck coupling reaction between N-
(m-tolyl)acrylamide (18) and precursor 16 was performed for the synthesis of compound 6, 
which has a trans stereochemistry as indicated by the large J constant between the two vinylic 
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protons (14.8 Hz). This alkene was then reduced to the saturated analogue 5. Compound 10 was 
synthesized by hydrogenolysis of the C-Cl bond of compound 16. 
Scheme 1. Synthesis of compounds 1, from 3 to 7, and 10.a 
 
aReagents and conditions: (i) DMF, K2CO3, rt, 1h (for 1); MeCN, CuI, Cs2CO3, MW 120°C, 
1.5h (for 3); DMF, K2CO3, 45°C, 18h (for 4); MeCN, K2CO3, 0°C, 0.5h then: rt, 3h (for 7 and 8); 
(ii) DMF, Pd(OAc)2, TBAB, (o-tol)3P, NaOAc, 145°C, 18h; (iii) EtOAc, H2, Pd/C, rt, 11h; (iv) 
NaOAc, MeOH, H2, PdCl2, rt, 36h 
Precursors 17d and 17e were prepared through the neat acylation of 3-methyl-aniline (19) with 
either mercapto-propionic acid (20) or dihydrothiophen-2(3H)-one (21) respectively (Scheme 2). 
Intermediate 18 was obtained through the acylation of 3-methyl-aniline (19) with acryloyl 
chloride (22, Scheme 2). 
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Scheme 2. Synthesis of precursors 17d, 17e and 18.a 
 
aReagents and conditions: (i) rt, 1h, then MW, 180°C, 1h; (ii) MW 120°C → 240°C, 28h; (iii) 
TEA, THF, 0°C, 2.5h 
Final products 12, 13, 14 and 15 were synthesized by aromatic nucleophilic substitution on the 
appropriate aromatic electrophile 23a-d with the nucleophile 2-mercapto-N-(m-tolyl)acetamide 
(17a) in acetonitrile, as shown in Scheme 3.  
Scheme 3. Synthesis of compounds 12, 13, 14 and 15.a 
 
aReagents and conditions: (i) MeCN, K2CO3, rt, 30min (for 12); MeCN, NaOAc, rt, 18h then 
40°C, 5d (for 13); MeCN, K2CO3, rt, 5h (for 14); MeCN, K2CO3, 0°C to rt, 2.5h (for 15) 
A different synthesis approach was required for compound 11. As shown in Scheme 4, the 
pyridone 24 was chlorinated with POCl3 to yield 2-chloro-4,6-diphenylpyridine (25), which then 
reacted with thiol (17a) through a Cu-catalysed aromatic nucleophilic substitution, giving the 
final product (11). 
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Scheme 4. Synthesis of compound 11.a 
 
aReagents and conditions: (i) POCl3, reflux, 4d; (ii) DME, CuI, L-proline, K2CO3, reflux in 
sealed ampule, 30h 
Scheme 5 reports the synthetic strategy used for compounds 2 and 9. The precursor 2-chloro-1-
morpholinoethanone (28) was synthesized through the reaction of morpholine (26) with 
chloroacetylchloride (27). Then, 4,6-diphenylpyridine-2-thiol (29) was used as a nucleophile in 
the nucleophilic substitution on 28 or iodomethane for the synthesis of the final products 2 and 9 
respectively.  
Scheme 5. Synthesis of compounds 2 and 9.a 
 
aReagents and conditions: (i) K2CO3, THF, 0°C to rt, 1h; (ii-a) DMF, Cs2CO3, TBAI, rt, 1h; (ii-
b) 0°C to rt, 2h 
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Biological evaluation of the compounds. 
All the synthesized molecules were evaluated for their inhibitory activity against the PA-PB1 
interaction. The abilities of the test compounds to inhibit the physical interaction between PA 
and PB1 and to block Flu virus replication were tested in Enzyme-Linked Immunosorbent 
Assays (ELISA) and in plaque reduction assays (PRA) in Mardin-Darby Canine Kidney 
(MDCK) cells infected with FluA virus (A/PR/8/34 strain), respectively. In order to exclude the 
possibility that the observed antiviral activity might be due to toxic effects on the infected cells, 
compound cytotoxicity was also assessed in two cell lines (MDCK and human embryonic 
kidney, HEK 293T) by the MTT assay. In these studies, the PB1(1-15)-Tat peptide37 was used as 
positive control for inhibition in the ELISA assay, while the broad-spectrum inhibitor of RNA 
viruses polymerases Ribavirin (RBV)38 was used as a positive control in the PRA assay as it 
inhibits viral polymerases even though its mechanism of action does not involve the inhibition of 
PA-PB1 formation. Moreover, the first line therapeutic NA inhibitor Oseltamivir (OSV)39 was 
also used as a positive control in the PRA assay. The results of the experiments are shown in 
Table 1. Most importantly, the data revealed for the first time not only that the chemical scaffold 
studied in this hit optimization process is able to inhibit the formation of the FluA PA-PB1 
complex with comparable IC50 with respect to the control (PB1(1-15)-Tat peptide), but also that it 
exhibits a good cytotoxicity profile and a low micromolar antiviral activity, comparable to RBV. 
Despite less efficicient antiviral activity was recorded for our compound family with respect to 
OSV, the family of compounds presented here inhibits a target that is less prone to mutations 
than NA, for which resistance is already emerging. Thus, they represent a promising class of 
molecules for the development of anti-influenza agents. 
 
 12 
Table 1. Structure and biological activity of the synthesized compounds. 
 
 
       
Cytotoxicity 
(MTT assay)c 
 
Compd R1 R2 R3 Z 
ELISA PA-
PB1 
Interaction 
Assay 
PRA in 
MDCK cells 
HEK 293T 
cells 
MDCK cells SIf 
     IC50 (µM)a EC50 (µM)b CC50 (µM)d CC50 (µM)e  
1 
   
CCN 175 ± 22 9.2 ± 0.7 >250 >250 >27.2 
2 
   
CCN 177 ± 20 100 ± 9 184 ± 14 >250 >2.5 
3 
   
CCN >200 93.9 ± 7.8 >250 >250 >2.7 
4 
   
CCN >200 28.6 ± 4.9 >250 >250 >8.7 
5 
   
CCN >200 >100 140.0 ± 7.8 >250 NC 
6 
   
CCN 190 ± 31 70.7 ± 5.7 >250 >250 >3.5 
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7 
   
CCN 122 ± 19 >10g 150 ± 14 13.9 ± 2.0 NC 
8 
   
CCN 140 ± 22 8.2 ± 1.1 95.6 ± 15.8 41.5 ± 5.4 5.1 
9 
   
CCN 195 ± 15 >50 144 ± 22 125 ± 16 NC 
10 
  
H CCN 116 ± 26 45.1 ± 3.0 >250 105 ± 7 2.3 
11 
   
CH 52.6 ± 9 7.3 ± 1.3 >250 150 ± 19 20.5 
12 H 
  
CCN >200 >10g 32.0 ± 3.6 7.1 ± 1.1 NC 
13 
 
H 
 
CCN >200 >10g 180 ± 5 41.5 ± 4.2 NC 
14 
   
N 165 ± 18 3.5 ± 0.5 22.3 ± 1.8 10.1 ± 1.7 2.9 
15 
   
N >200 26.5 ± 4.3 >250 >250 >9.4 
RBV     ND 12.8 ± 2.1 >250 >250 >19.5 
OSV     ND 0.015 ± 0.006 >250 >250 >16000 
PB1(1–
15)–Tat 
peptide 
    35.9 ± 5.6 49.7 ± 5.1 >250 >250 >5.0 
aActivity of the compounds in the ELISA PA-PB1 interaction assays. Values represent the compound concentration (in µM) that 
reduces the interaction between PA and PB1 by 50% (IC50). bAntiviral activity of the compounds in plaque reduction assays against 
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the Flu A/PR/8/34 strain. Values represent the compound concentration (in µM) that inhibits 50% of plaque formation (EC50). 
cCytotoxicity of the compounds exhibited in the MTT assays. Values represent the compound concentration (in µM) that causes a 50% 
decrease in cell viability (CC50). dCC50 assessed in HEK 293T cells. eCC50 assessed in MDCK cells. fSelectivity index, defined as the 
ratio between the CC50 value assessed in MDCK cells and the EC50 value. gCompound concentrations higher than those reported could 
not be tested in PRA due to cytotoxicity. All values represent the averages ± SD of data derived from at least three independent 
experiments in duplicate. ND: not determined. NC: not calculated because of cytotoxicity or absence of antiviral activity at tested 
concentrations. 
 
 
 15 
Lower activity in the ELISA experiments compared to the PRA assays could be observed, in 
particular for compounds 1, 4, 14 and 15. Compounds 1 and 14 exhibited a low-micromolar EC50 
value in PRA (9.2 and 3.5 µM, respectively) and a 19-47−fold higher IC50 value in ELISA (175 
and 165 µM, respectively), while 4 and 15 presented an EC50 around 30 µM in PRA (28.6 and 
26.5 µM, respectively) and complete loss of the ability to disrupt the PA-PB1 interaction in 
ELISA. In order to investigate whether this could be due to the conditions, the ELISA assay was 
repeated for all molecules with EC50 values below 30 µM (1, 4, 8, 11, 14, 15). In this assay 
(henceforth mentioned as “Modified ELISA PA-PB1 Interaction Assay”), compounds were 
dissolved in a similar medium to the one used in the cell-based assays instead of the PBS buffer 
(see Experimental Section). Similarly to the previous ELISA PA-PB1 Interaction Assay, the 
PB1(1-15)-Tat peptide37 was used as a positive control for inhibition. As reported in Table 2, a 
significant improvement in the inhibitory activity was obtained mainly for 1 and 15, which were 
more soluble in the DMEM serum-free buffer with respect to the PBS one, while more modest 
improvements were obtained for 11 and 14. The same IC50 values were obtained for compounds 
4 and 8. As expected, comparable IC50 values were also obtained for the PB1(1-15)-Tat peptide in 
the two assay conditions, suggesting that the medium was affecting the behaviour of some of our 
compounds rather than the accessibility of the target site.  
Table 2. Inhibitory activity of selected compounds on the PA-PB1 interaction in the modified 
ELISA. 
Compd 
Modified ELISA PA-
PB1 Interaction Assay 
IC50 (µM)a 
1 35.2 ± 5.1 
4 >200 
 16 
8 145±24.0 
11 40.5±15.6 
14 113 ± 15 
15 64.5 ± 5.4 
PB1(1–15)–Tat 
peptide 
31.7±10.8 
aAbility of the compounds to inhibit the PA-PB1 interaction in the ELISA performed with the 
DMEM serum-free medium in place of the PBS buffer. Values represent the compound 
concentration (in µM) that reduces the interaction between PA and PB1 by 50% (IC50). Values 
represent the averages ± SD of data derived from at least two independent experiments in 
duplicate. 
Data presented in both Table 1 and Table 2 are of great value for the understanding of the 
general mechanism of action of the 3-cyano-4,6-diphenyl-pyridine scaffold. A significant 
decrease in activity was observed in the attempts of substituting the sulphur atom (3, 4, 5 and 6), 
indicating the importance of this heteroatom. Only for compound 4 the antiviral activity was 
partially retained. The whole sulphur-containing side chain appears to be also essential as its 
complete (10) or its partial (9) removal resulted in a reduction or a complete loss of activity. 
Nevertheless, a modest antiviral activity was observed for compound 10. However, considering 
its significant cytotoxicity in MDCK cells and the high IC50 value in the ELISA assay, its 
antiviral activity in PRA might be related to cell toxicity rather than to the inhibition of PA-PB1 
interaction. This hypothesis is in keeping with the observation that the compound 10 lacks of one 
of the interaction with a relevant hydrophobic area within the PA binding region. Only one 
methylene group should be placed between the sulphur atom and the carbonyl moiety, as the 
extension of the chain (7 and 8) increased cytotoxicity. Furthermore, the 3-methyl substituted 
phenyl ring cannot be replaced by a more hydrophilic group, as indicated by the increased EC50 
value of compound 2. Given the inactivity and the higher cytotoxicity of 12 and 13, the two 
phenyl rings directly attached to the pyridine ring (in positions 4 and 6) appear to be essential in 
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the molecular scaffold. Interestingly, the removal of the cyano moiety linked to the same central 
core (11) did not affect activity. Good antiviral activity was observed also with the substitution 
of the pyridine ring with a pyrimidine one (14), but a lower ability to dissociate the PA-PB1 
complex and a higher cytotoxicity were detected as well. However, this toxicity decreased with 
the introduction of two electron withdrawing CF3 groups in the structure (15). For this 
compound, a better IC50 value was obtained in the modified ELISA, but a worse antiviral activity 
profile in respect to compounds 1, 8, 11, and 14 was also detected. 
From these results, compounds 1, 11, and 15 emerged as the most promising molecules since 
they display micromolar inhibition of the PA-PB1 interaction (with IC50 values ranging from 
35.2 to 64.5 µM), interesting antiviral activity and a good cytotoxicity profile with a selectivity 
index (SI) higher than 9.4. Among the other compounds, 4 showed a antiviral activity 
comparable to 15 and a good cytotoxicity profile (SI > 8.7), but no inhibition of the PA-PB1 
interaction. Thus, aiming to better understand mechanism of action of these compounds, the 
ability of compounds 1, 4, 11 and 15 to inhibit FluA RNA-dependent RNA polymerase (RdRp) 
enzymatic activity in a cellular context was assessed by minireplicon assays in transfected HEK 
293T cells, using RBV38 as a reference inhibitor. The results are presented in Table 3. All of the 
tested compounds were found to inhibit the viral polymerase activity, with encouraging EC50 
values for compounds 11 and 15 (22.0 to 30.8 µM) in particular. Furthermore, from the results it 
emerges that compound 1, in addition to inhibiting the PA-PB1 interaction, might be involved in 
other mechanisms of action not related to the viral polymerase activity because its low EC50 
value in the PRA assay (9.2 µM) does not reflect completely the activity in the minireplicon 
assay (EC50 86.6 µM). Compound 4 inhibited the viral RdRp in the 293T cells (EC50 46.3 µM), 
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indicating that this molecule might exert its antiviral activity through the inhibition of the viral 
RdRp, but through a mechanism of action that does not involve the PA-PB1 complex disruption.  
 
Table 3. Activity of the selected compounds in the minireplicon assay. 
Compd 
Minireplicon Assay 
EC50 (µM)a 
1 86.6 ± 15.0 
4 46.3±8.7 
11 30.8 ± 5.3 
15 22.0 ± 4.1 
RBV 23.8 ± 4.5 
aThe EC50 values represent the compound concentration that reduces by 50% the activity of 
FluA virus RNA polymerase in HEK 293T cells. All values represent the averages ± SD of data 
derived from at least two independent experiments in duplicate. 
The ability of these compounds to inhibit the polymerase activity in cells as well as the PA-
PB1 interaction and the formation of viral plaques is a substantial indication that the most 
promising 4,6-diphenyl pyridine (or pyrimidine) molecules exert their anti-influenza activity 
through the disruption of the PA-PB1 complex.  
Molecular modelling. 
In order to rationalize the SARs, all the synthesized compounds were examined by means of 
docking simulations within the PB1-binding site of PA in order to produce their putative binding 
poses.  
The 3-cyano-4,6-diphenyl pyridine series was discovered with a previous high-throughput 
docking study performed on a homology model built using the FluA H1N1 sequence and two 
PA-PB1 complexes templates (PDB IDs: 2ZNL20 and 3CM821).35 Subsequent to the publication 
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of the manuscript by Tintori et al.,35 a novel X-ray structure of FluA H17N10 RdRp was 
published (PDB ID: 4WSB)23 and comprised the whole PA in complex with PB1, PB2 and a 
viral RNA promoter. Since the C-terminal portion of PA (PAC) in 4WSB is more complete than 
the structures used to build the PA-PB1 complex in silico (2ZNL and 3CM8), the two PAC were 
compared in order to assess the quality of the homology model. The two structures have 71.21% 
identity in sequence alignment and they superpose very well (RMSD 1.09Å). Remarkably, the 
superposition is even better in the PB1-binding site region (RMSD of 0.537Å), validating the 
reliability of the homology model. The backbone superposition of the homology model and PDB 
ID 4WSB is shown in Figure S1 of the Supplementary Information. Since biological evaluations 
were performed on the FluA H1N1 strain, and since the homology model was assessed of good 
quality, for consistency purposes the homology model was used for the docking simulations. 
Similarly to the procedure applied in the previous study,35 docking simulations were carried 
out with two widely used programs (Glide40 and GOLD41) and the binding poses were then 
compared. Most importantly, only the active compounds reproduced the already reported binding 
model35 of the 3-cyano-4,6-diphenyl-pyridine derivatives, confirming the proposed mode of 
binding of this class of inhibitors. The pose obtained for compound 1 is shown in Figure 1 as an 
example. In this model, two hydrogen bonds between the amide portion of the ligands and 
residues Gln408 and Val621 resemble PB1-PA interactions. When present in the ligand, a third 
hydrogen bond occurs between the CN nitrogen of the compound and Lys643 side chain amine. 
The three phenyl rings are accommodated in three hydrophobic areas indicated as I (Val621, 
Phe411 and Cys415), II (Pro620, Val628 and His713) and III (Phe658, Leu666, Phe707 and 
Phe710) in the figure. A further hydrophobic interaction involves Trp706 and the pyridine (or 
pyrimidine) ring of the small molecule.  
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Figure 1. Binding pose for compound 1 (orange sticks). 
Two examples of bad ligand placements within the binding site are shown in Figure 2, where 
the conformations of 12 and 3 (cyan sticks) are compared with that of compound 1 (orange 
sticks). As previously discussed, compounds lacking of important portions of compound 1 were 
not able to reproduce fundamental protein-ligand interactions in the docking simulations. In 
particular, the increase of IC50 values of molecules lacking of either one of the phenyl groups 
that interact with the protein regions II and III could be explained by the impossibility to form 
any of the important interactions, most of the times presenting a completely different binding 
mode, as exemplified in panel A in Figure 2. With the substitution of the sulphur atom 
(compounds 3-5) and with the introduction of a double bond (6) the effective interactions were 
sometimes partially reproduced (exemplified in panel B in Figure 2) or completely lost. The 
different geometry properties of the atoms substituting the sulphur atom and of the C-C double 
bond do not allow the small molecule to assume a suitable conformation for correct binding, 
resulting in a bad docking pose and explaining the inactivity of these molecules.  
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Figure 2. Examples of bad binding of inactive compounds. In both images compound 1 (orange 
sticks) is used as a reference. A) Binding pose of compound 12 (cyan sticks). B) Binding pose of 
compound 3 (cyan sticks). 
Compounds 11, 14 and 15, all lacking the nitrile group, were able to reproduce all the 
important interactions, except the hydrogen bond with Lys643, thus overlapping very well with 
the binding pose of 1 (Figure 3). The overlapping binding poses of compounds 11, 14 and 15 can 
be found in Figure S1 of the Supplementary Information. From the binding model, we expected 
that the lack of the hydrogen bond with Lys643 would result in a less favourable binding of the 
small molecules to PA, with a decrease in the ability to disrupt the PA-PB1 interaction, but this 
was not confirmed by the biological data. Thus, the PA-compound complexes for the most 
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promising compounds (1, 11 and 15) were further investigated by means of molecular dynamics 
(MD) using Schrödinger Desmond.42  
 
Figure 3. Binding pose of compounds 1 (orange sticks) and compound 11 (cyan sticks) from 
docking simulations. 
After extensive equilibration, a 14ns MD simulation was performed for each complex starting 
form the most representative docking pose. The evolution in time of the root-mean-square 
deviation (RMSD) calculated on the backbone atoms of the protein in respect to the starting 
structure is presented in panel A of Figure 4. After an initial increase due to further equilibration 
of the complex, the RMSD values were less variable in both simulations, in particular for the 
compound 11 in complex with PA, whose RMSD stabilised around 3.19Å after 3ns of 
simulation. For the molecular system containing compound 1 the average RMSD calculated 
between 2 and 8ns was 2.61Å, while it increased up to 3.44Å (at 12ns) after this time period. 
RMSD average values for the PA-15 complex were 2.15Å and 2.77Å between 3 and 8 ns and 
after 8 ns respectively. The root-mean-square fluctuations (RMSFs) of the backbone atoms were 
then evaluated on the whole trajectories. As shown in panel B of Figure 4, the RMSF trends were 
the same for the three systems. Predictably, high fluctuations were recorded for the protein 
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portions (residues 349-353, 372-388, 389-396 and 550-557) that were not solved in the original 
crystal structure (PDB ID 2ZNLk). Higher values generally corresponded to random coils and did 
not include residues interacting with the ligands (highlighted in purple), suggesting that the 
structure of PB1-binding site within PA was stable during the production MD. This was further 
supported by cluster analysis that indicated high similarity of the binding site conformation 
between the clusters. Figure 5 shows the superposition of the average structures of the ten 
clusters obtained for compound 1, 11 and 15 complexes (panels A, B and C respectively). In all 
panels, one structure of the ligand (in sticks) is shown for a better identification of the binding 
site. 
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Figure 4. A) Time evolution of the backbone atoms RMSD values for the complexes between 
PA and compounds 1 (blue line), 11 (red line) and 15 (green line). B) RMSF evaluation of the 
backbone atoms for the complexes between PA and compounds 1 (blue line), 11 (red line) and 
15 (green line). Ligand contacts are highlighted in purple. 
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Figure 5. Superposition of the average structures of the 10 clusters obtained by cluster analysis. 
Protein backbone is shown as ribbon and the ligand structure in sticks. A) Clusters for the PA-
compound 1 complex. B) Clusters for the PA-compound 11 complex. C) Clusters for the PA-
compound 15 complex. 
For a more detailed analysis of the stability of the PA-ligand complexes, the interactions 
between the protein and the small molecules were investigated on the whole 14ns simulation 
time. Occupancy percentages were also calculated and are listed in Table 4. Hydrogen bonds and 
ionic interactions were the most stable contacts between PA and the ligand, with occupancy 
higher than 60%, whereas hydrophobic interactions were generally weaker (occupancy less than 
30%). An exception was the hydrophobic interaction with Trp706 that resulted to be stable and 
important, particularly for compound 11 (65.90% occupancy) and secondly for compound 15 
(50.72% occupancy). Predictably, the ionic contact between Lys643 side chain amine group and 
the compounds was much more important in the complex between the protein and 1, where the 
interaction involved the CN group of the small molecule. Differently, negligible or weak ionic 
contacts occurred between Lys643 and the sulphur atom of 11 and 15 respectively. Not predicted 
by the docking simulation, a π-cation contact between Lys643 side chain amine and the phenyl 
moiety in position 4 in the pyridine core of the ligands was detected and it appeared more stable 
for compound 1 (74.54% versus 31.30% occupancy for 11). This interaction was however 
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negligible for compound 15 (3.54% occupancy), where the π-cation contact was compensated by 
a stronger ionic interaction of Lys643 with the sulphur atom (25.88% occupancy) and by a weak 
hydrogen bond between Lys643 and the carbonyl oxygen of the ligand (15.78% occupancy). 
Importantly, Lys643 was also involved in a water-bridge contact with the pyrimidine nitrogen in 
position Z (according to Table 1; henceforth named N1) of compound 15 with 46.09% 
occupancy, while this type of interaction is not possible for compounds 1 or 11.  
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Table 4. Ligand interactions occupancies for 1 and 11 in complex with PA. 
Residue(atom)a 
Ligand 
atom/group 
Type of 
contactb 
Occupancy (%)c 
Comp 1 Comp 11 Comp 15 
Val621(O) NH bbHB 25.10 98.36 24.97 
Gln408(HE) O scHB 22.04 97.05 14.68 
Lys643(NZ) CN or S I 56.35 6.38 25.88 
Lys643(HZ) O scHB 0.00 0.00 15.78 
Lys643 4-phenyl Pcat 74.54 31.30 3.54 
Trp706 pyridine Hyd 35.41 65.90 50.72 
Phe411 3-Me-phenyl Hyd 16.80 15.63 27.31 
Phe411 3-Me-phenyl PP 30.29 1.23 33.20 
Cys415 3-Me-phenyl Hyd 5.93 6.72 3.60 
Pro620 6-phenyl Hyd 4.15 0.24 0.00 
Val628 6-phenyl Hyd 3.22 0.79 3.05 
Leu666 4-phenyl Hyd 2.88 2.47 0.79 
Phe707 4-phenyl Hyd 23.69 12.61 30.02 
Phe710 4-phenyl Hyd 46.97 24.16 19.01 
Phe710 4-phenyl PP 25.77 29.66 17.75 
His713 4-phenyl PP 10.04 14.20 0.00 
Lys643 N1c WB NA NA 46.09 
aOnly for hydrogen bonds and ionic contacts, the interacting atom is reported in brackets using 
the following abbreviations: O=backbone oxygen; HE=hydrogen of the side chain amide; 
NZ=nitrogen of the side chain amine; HZ=hydrogen side chain. bType of interaction between the 
protein and the ligand. Abbreviations used: bbHB=hydrogen bond with residue backbone; 
scHB=hydrogen bond with residue side chain; I=ionic interaction; Pcat=π-cation interaction; 
Hyd=Hydrophobic interaction; PP=π-π stacking; WB=water bridge. cN1= pyrimidine nitrogen in 
position Z in the compound, according to Table 1 numeration. dPercentage of trajectory frames in 
which the interaction was recorded; NA=not applicable. 
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Remarkably, hydrogen bonds between the amide portion of compound 11 and Val621 
backbone oxygen and Gln408 side chain amide hydrogen presented occupancy values close to 
100%; while the same interactions in the other PA-compound complexes were much weaker, 
with occupancy lower than 30%. From the visualization of the trajectories a change of 
conformation of 1 and of 15 were observed. In the PA-compound 1 trajectory, while the 
interaction between the ligand’s CN group and Lys643 occurred during the whole duration of the 
simulation, the hydrogen bonds with Val621 and Gln408 broke after approximately 4ns. An 
approximately 1.7Å shift of the pyridine core of 1 weakened the interaction of Trp706, placed 
the phenyl ring in position 4 in the pyridine in a more suitable area for the π-cation contact with 
Lys643 and enhanced the hydrophobic interactions with the areas II and III, explaining the 
higher occupancy values for these contacts (Lys643 π-cation contact and Phe707 and Phe710 
hydrophobic interaction in particular). Furthermore, lacking the constraints given by the 
hydrogen bonds involving the ligand’s amide moiety, the methyl-substituted phenyl ring was 
able to give weak T-shaped π-π stacking with Phe411 in the hydrophobic area I. As an example 
of this change in conformation, panel A of Figure 6 shows the superposition of a frame saved 
from the trajectory after 4.8ns of simulation with the starting structure of the PA-compound 1 
complex. Similarly to what observed for the system containing compound 1, after approximately 
3.7ns, a 2.3Å shift of the central aromatic ring occurred in the PA-15 simulation. Also in this 
case, the change in binding mode weakened the interaction with Trp706, increased the 
hydrophobic interactions with the areas II and III, with residues Phe411 and Phe707 in particular, 
and allowed the establishment of a weak T-shaped π-π stacking with Phe411. However, in this 
simulation Lys643 did not give a π-cation interaction with the phenyl moiety, but it interacted 
with 15 through a direct hydrogen bond (with the carbonyl oxygen) and a water bridge (with the 
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pyrimidine N1 nitrogen), mainly after the compound shift. Interestingly, the water molecule that 
bridges the interaction between Lys643 and N1 overlaps very well the CN nitrogen of compound 
1 when the structures of the two complexes extracted after 4ns simulation are superposed (panel 
B of Figure 6). Thus, in the case of compound 15, the water molecule had the same role of the 
CN group of 1 in the interactions with the protein and this explains why the MD simulation for 
the PA-15 system was more similar to the one containing 1 than to the one containing 11.  
  
Figure 6. A) Change in protein-ligand interactions during the MD simulation of 1 in complex 
with PA. The ligands and the protein residues discussed in the text are shown as sticks and as 
lines respectively. Carbon atoms of the starting complex structure are coloured in orange; while 
the ones of the saved MD trajectory frame are in light blue. Lighter shades of the same colour 
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were used for protein carbon atoms. Hydrogen bonds are indicated in red. B) Superposition of 
the PA-compound 1 and PA-compound 15 complexes extracted after 4ns of simulation. Similar 
representation to panel A was used here. Carbon atoms of compound 1 are coloured in light blue; 
while the ones of compound 15 are in pink. The same colour was used for protein carbon atoms. 
The water molecule mentioned in the text is represented in sticks. 
Taken together, the results from the MD simulations suggest that the decrease in binding 
affinity caused by the lack of the ionic contact between the CN group and Lys643 side chain 
amine is compensated by CN-lacking compounds that display an interesting activity in two 
possible ways according to the central scaffold. In the case of a pyrimidine central ring (15), N1 
allows the establishment of a water bridge that mimics the CN group. For pyridine scaffolds 
(11), that do not allow this interaction, a more stable binding conformation with stronger 
interactions with other critical residues (Val621, Gln408 and Trp706 in particular), explains the 
comparable activity exhibited by the two compounds.  
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CONCLUSIONS 
The increasing resistance for the current therapy against influenza infection makes the 
discovery of novel drugs with a different mechanism of action compelling.15 The viral RNA 
polymerase is not only essential for the viral genome replication and transcription, but also less 
prone to genetic variability than the current therapeutic targets. Its activity requires the formation 
of the PA-PB1 complex, making the inhibition of this protein-protein interaction an attractive 
antiviral strategy. In this work, a hit optimization process was applied to previously identified 
small molecules with a 3-cyano-4,6-diphenyl pyridine scaffold that were identified as promising 
PA-PB1 PPI.35 The molecular scaffold was systematically modified and synthetic strategies were 
developed. The biological evaluation of the 15 synthesized compounds allowed the 
determination of structure-activity relationships and showed for the first time that this novel class 
of molecules with a 4,6-diphenyl pyridine (or pyrimidine) nucleus is able to inhibit the viral 
polymerase through the disruption of the PA-PB1 interaction and that this can result in an 
antiviral effect with a good toxicity profile. The biological assays results indicated that the two 
phenyl rings in position 4 and 6 are essential for antiviral activity, while the removal of the CN 
moiety at position 3 does not affect compound activity. Furthermore, the modification of the 
sulphur-containing side chain produces a decrease or complete loss in the inhibition of the PA-
PB1 interaction. Interestingly, some of these compounds retain some antiviral activity, indicating 
a change in the mechanism of action for them. SAR indications were rationalised by means of 
docking and molecular dynamics simulations that confirmed that compounds bind to the PB1-
binding site within the C-terminal portion of PA and that the most important interactions involve 
Lys643, Gln408, Val621, Trp706 and three hydrophobic areas (I, II and III).  
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Encouragingly, three compounds (1, 11 and 15) that act on a target that is less prone to 
mutations than the ones used in current therapy were identified in this work. These are promising 
anti-influenza molecules that will be further developed in the future, using the binding model and 
the identified SAR. 
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EXPERIMENTAL SECTION 
Computational details. 
Protein preparation.  
The homology model prepared for the previous study35 was used as the structure for the 
influenza A PA-PB1 complex. Briefly, the available structures of the C-terminal portion of 
H5N1 and H1N1 influenza A virus PA (PAC) in complex with the N-terminal PA-binding region 
of PB1 (PB1N, residues 1-25) were downloaded from the Protein Data Bank (PDB ID: 2ZNL20 
and 3CM821 respectively). Since both structure present gaps, a more complete PAC was obtained 
by means of homology modelling using the Prime tool of the Schrödinger suite.43 The model was 
built of the FASTA sequence of the protein (influenza A virus, strain A/Wilson-Smith/1993 
H1N1), using PDB IDs 2ZNL as the first template and 3CM8 as the second one. When possible, 
the missing portions of 2ZNL were thus filled using 3CM8 corresponding coordinates, while the 
missing residues in both structures were modelled by the program according to the FASTA 
sequence. In order to remove unfavourable contacts, the model was then energy minimized using 
the all-atom OPLS force field and Polak-Ribiere conjugate gradient method. Water was used as a 
solvent, applying a continuum solvation method. Convergence was set to 0.3 kJmol-1 and 
extended cut-offs were used.  
Protein structure comparison. 
The X-ray crystal structure of the Influenza A virus H17N10 PA-PB1-PB2 trimer in complex 
with the viral RNA promoter was downloaded from the Protein Data Bank (PDB ID: 4WSB).23 
The C-terminal portion of PA (PAC) was used for comparison with that of the homology model. 
PyMOL44 was used for structure superposition. The alignment of the residue sequences saved 
from the superposition was assessed with Clustal Omega web server.45 
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Ligand preparation. 
All small molecules were built with the Schrödinger Maestro graphical interface.46 The 
structures were then processed with Schrödinger LigPrep tool47 generating for each ligand all 
feasible tautomers and assigning with Epik all possible protonation states at pH 7.0 ± 2.0, using 
all atom OPLS force field.  
Docking simulations. 
Docking simulations were performed with two programs: Glide40 and GOLD.41 In the docking 
computed with Glide, the receptor grid was built on the PA-PB1 complex and centred on the 
PB1 peptide derived from the crystal structure. The dimensions of the box were set to 12Å. 
Default settings with flexible SP mode were chosen for the docking simulation. Generated poses 
were minimised after docking and a maximum of 5 low energy poses were saved for each entry. 
The docking simulations with GOLD were performed using GoldScore and ChemScore fitness 
functions. The search efficiency was set to 200% and results differing less than 1.5Å in ligand 
all-atom RMSD were clustered together. Also in this case five poses were saved for each entry. 
All poses were visually inspected and consensus poses were used for SAR determination. 
Molecular Dynamic Simulation (MD). 
The Molecular Dynamics simulations were performed on the protein-ligand complexes 
involving compounds 1, 11 and 15. Starting structures were retrieved from the most 
representative docking poses results. The simulation setup was performed by means of the 
System Builder of Schrödinger Desmond.42 The simulation box was orthorhombic with the 
minimum possible volume. A TIP4P water model and the all atom OPLS force field were used. 
The system was neutralised and a salt (NaCl) concentration of 0.15 M was added to the system. 
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The simulations were performed in PBC conditions. Prior production, a total of 4ns of 
equilibration was performed. The first step of equilibration was a 1ns NVT Brownian simulation 
at 10K temperature, restraining the solute heavy atoms. All the following steps used the 
Langevin algorithm. The second step of equilibration was performed restraining solute heavy 
atoms in NVT conditions for 0.5ns at 10K with Berendsen temperature coupling, using a 0.1 
coupling constant. In the third stage solute heavy atoms were restrained in NPT conditions for 
0.5ns at 10K and 1atm with Berendsen temperature and pressure coupling, using a 0.1 and 50.0 
coupling constants for temperature and pressure respectively. Then, solute heavy atoms were 
restrained in NPT conditions for 1ns at 300K and 1atm with Berendsen temperature and pressure 
coupling, using a 0.1 and 2.0 coupling constants for temperature and pressure respectively. No 
restraints and NPT conditions were set for the last equilibration step that lasted 1ns at 300K and 
1atm with Berendsen temperature and pressure coupling, using a 0.1 and 2.0 coupling constants 
for temperature and pressure respectively. All restraints were applied with a force of 50.0 
kcal/mol. A 14ns NPT production MD simulation was performed with a 2fs time step, collecting 
energy and trajectory data ever 1.2ps and 4.8ps respectively. The temperature was maintained at 
300K and pressure was maintained at 1atm using Langevin method with coupling constant of 2.0 
and 1.0 for pressure and temperature respectively. The PME method with 9.0nm cut-off radius 
was used for Coulombic interactions.  
The MD analysis was performed with the Desmond Simulation Quality Analysis and the 
Simulation Interaction Diagram tools.42 Cluster analysis was computed with the python script 
trajectory_clusters.py available in the Schrödinger suite. Ten clusters were identified, 
confronting all trajectory frames. 
Chemistry. 
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Chloride 16 was either bought from Advanced Chemical Intermediates Ltd or synthesized by 
us through a known procedure.48 Thiol 17a, alcohol 17b and amine 17c were obtained from 
Otava Ltd. Chlorides 23a and 23b were purchased from Fluorochem Ltd. Chloropyrimidine 23c, 
pyridone 24 and thiol 29 were prepared following literature protocols.49-51 All other chemicals 
were purchased from Sigma-Aldrich. THF, toluene, DME and DCM were distilled freshly from 
CaH2, all other solvents were used as received. Unless indicated otherwise, all reactions were 
carried out under an inert atmosphere. TLC analyses were performed with Merck F254 Alumina 
Silica Plates using UV visualization or staining. Microwave reactions were carried out on a 
Biotage Initiator. Column purifications were carried out manually using Silicycle Ultra Pure 
Silica Gel, Fluka silica gel 60 (0.04–0.063 mm) or automatically using the Biotage equipment. 
All HRMS spectra were recorded on Bruker micrOTOF MS using ESI in positive ion mode. The 
1H-, 13C- and 2D-NMR spectra were recorded on a Bruker 200, 250, 400, 500 or 600 MHz 
spectrometer. Systematic names for molecules were generated using ChemBioDraw Ultra 14. 
Unless specified otherwise, all final compounds have an LC purity  95 % at 254 nm. This was 
determined using a Shimadzu HPLC/MS workstation with a LC-20AD pump system, SPD-
M20A diode array detection and a LCMS-2010 EV Liquid Chromatograph Mass Spectrometer. 
Compound purities were calculated as the percentage peak area of the analysed compound by 
UV detection at 254 nm. The buffer used is a 0.4% (w/v) NH4HCO3 solution in water, adjusted 
to pH 8.0 with NH4OH. The column used is an Xbridge C18 5 μm column (50 mm × 4.6 mm). 
Solvents used in this paragraph: Solvent B=90% MeCN-10% buffer; Solvent A=90% water-10% 
buffer. The analysis was conducted using a flow rate of 1.0 mL/min, start 5% B, linear gradient 
to 90% B in 4.5 min, then 1.5 min at 90% B, then linear gradient to 5% in 0.5 min, then 1.5 min 
at 5% B, total run time of 8 min. 
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2-((3-Cyano-4,6-diphenylpyridin-2-yl)thio)-N-(m-tolyl)acetamide (1, VUF14465) 
To a stirred solution of chloride 16 (0.291 g, 1.00 mmol) in DMF (20 mL) was added thiol 17a 
(0.326 g, 1.80 mmol) and K2CO3 (0.207 g, 1.50 mmol). The resulting mixture was stirred for 1 h 
and then quenched with water (50 mL). The precipitate was filtered and dissolved in DCM. The 
solution was dried over Na2SO4, filtered and concentrated. The crude product was purified using 
flash chromatography (gradient starting from 5 % (1% Et3N/EtOAc) in heptane to 40 % (1% 
Et3N/EtOAc) in heptane). This yielded the product as a solid (110 mg, 25 %). 1H NMR (500 
MHz, CDCl3)  9.02 (s, 1H), 8.14 – 8.03 (m, 2H), 7.68 – 7.60 (m, 3H), 7.60 – 7.51 (m, 6H), 7.12 
– 7.00 (m, 2H), 6.81 (s, 2H), 4.14 (s, 2H), 2.15 (s, 3H). 13C NMR (126 MHz, CDCl3)  166.5, 
162.6, 159.6, 155.5, 138.8, 137.7, 137.2, 135.8, 131.3, 130.6, 129.6, 129.4, 128.9, 128.5, 127.7, 
125.1, 120.3, 117.4, 116.7, 115.2, 104.3, 35.2, 21.5. LCMS purity: 98+ %. HRMS [M+H]+ calc: 
436.1478, found: 436.1467. 
2-((2-Morpholino-2-oxoethyl)thio)-4,6-diphenylnicotinonitrile (2, BAS-88) 
A mixture of thiol 29 (173 mg, 0.600 mmol), Cs2CO3 (195 mg, 0.599 mmol) and TBAI (222 
mg, 0.601 mmol) and anhydrous DMF (8 mL) was stirred for 1 h at rt After cooling to 0 °C, 
chloride 28 (147 mg, 0.899 mmol) dissolved in DMF (0.4 mL) was added. The resulting mixture 
was allowed to warm to rt and stirred for 2 h. After dilution with cold water (30 mL) and 
extraction with DCM (3 x 20 mL), the combined organic layers were dried over MgSO4, filtered 
and concentrated. The residue was purified by column chromatography (acetone/DCM 5/95) to 
obtain the product as white solid (75 mg, 30%). 1H NMR (600 MHz, CDCl3) δ 8.05-8.01 (m, 
2H), 7.64-7.60 (m, 2H), 7.59-7.50 (m, 7H), 4.31 (s, 2H), 3.74-3.66 (m, 8H). 13C NMR (600 MHz, 
CDCl3) δ 166.2, 162.2, 158.8, 154.8, 137.4, 136.0, 130.7, 130.2, 129.1, 129.0, 128.4, 127.4, 
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116.5, 115.4, 103.8, 66.8, 66.6, 46.6, 42.7, 32.9. LCMS-purity: 95+ %. HRMS [M+H]+ calc: 
416.1427, found: 416.1434. 
2-((3-Cyano-4,6-diphenylpyridin-2-yl)oxy)-N-(m-tolyl)acetamide (3, VUF14467) 
A microwave tube was charged with chloride 16 (0.15 g, 0.52 mmol), alcohol 17b (0.077 g, 
0.47 mmol), CuI (8.9 mg, 0.047 mmol) and Cs2CO3 (0.229 g, 0.704 mmol). The tube was 
thoroughly flushed with N2. MeCN (5 mL) was added and the mixture was exposed to μW 
radiation (120 oC, 1.5 h). The reaction mixture was concentrated under reduced pressure. The 
remaining solids were subjected to extraction with EtOAc / water (3x50 mL). The organic layer 
was dried over MgSO4, filtered and concentrated. The crude product was purified by column 
chromatography using EtOAc:heptane 2:8 and then (EtOAc:Et3N 99:1) : heptane 25:75. This 
afforded the product as a solid (14 mg, 6 %). 1H NMR (500 MHz, DMSO-d6)  10.35 (s, 1H), 
8.23 – 8.15 (m, 2H), 7.87 (s, 1H), 7.80 – 7.74 (m, 2H), 7.64 – 7.58 (m, 3H), 7.48-7.45 (m, 2H), 
7.40-7.37 (m, 3H), 7.21 (t, J = 7.8 Hz, 1H), 6.89 (d, J = 7.5 Hz, 1H), 5.17 (s, 2H), 2.27 (s, 3H). 
13C NMR (126 MHz, DMSO-d6)  166.1, 163.3, 157.0, 156.6, 138.5, 138.0, 136.3, 135.8, 130.8, 
130.2, 128.9, 128.8, 128.7, 127.5, 124.2, 120.0, 116.6, 115.2, 114.2, 92.3, 65.7, 21.2, two carbon 
signals likely overlap. LCMS purity: 95+ %. HRMS [M+H]+ calc: 420.1707, found: 420.1702. 
2-((3-Cyano-4,6-diphenylpyridin-2-yl)amino)-N-(m-tolyl)acetamide (4, VUF14466) 
To a stirred solution of chloride 16 (0.210 g, 0.722 mmol) in DMF (20 mL) was added amine 
17c (0.214 g, 1.30 mmol) and K2CO3 (0.150 g, 1.09 mmol). The resulting mixture was stirred for 
18 h at 45 oC and then quenched with water (50 mL). Water and DMF were evaporated and the 
residue was dissolved in DCM. This solution was dried (Na2SO4), filtered and concentrated. The 
crude product was purified using flash chromatography (gradient starting from 10% (1% 
Et3N/EtOAc) in heptane to 80% (1% Et3N/EtOAc) in heptane). The product was collected and 
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again subjected to the same purification procedure. This yielded the product as a solid (14 mg, 5 
%). 1H NMR (500 MHz, CDCl3)  8.48 (s, 1H), 8.06 – 8.04 (m, 2H), 7.68 – 7.60 (m, 2H), 7.58 – 
7.50 (m, 3H), 7.48-7.46 (m, 3H), 7.29 (s, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.19 (s, 1H), 7.14 (t, J = 
7.8 Hz, 1H), 6.88 (d, J = 7.4 Hz, 1H), 6.06 (t, J = 5.5 Hz, 1H), 4.40 (d, J = 5.6 Hz, 2H), 2.25 (s, 
3H). 13C NMR (126 MHz, CDCl3)  168.1, 159.1, 158.8, 155.7, 139.0, 137.6, 137.5, 136.8, 
130.7, 130.2, 129.2, 129.1, 129.0, 128.3, 127.5, 125.3, 120.7, 117.1, 116.9, 111.4, 89.9, 47.4, 
21.5. LCMS purity: 99+ %. HRMS [M+H]+ calc: 419.1866, found: 419.1861. 
3-(3-Cyano-4,6-diphenylpyridin-2-yl)-N-(m-tolyl)propanamide (5, VUF14519) 
A mixture of 6 (63 mg, 0.15 mmol) and 5 % Pd/C (5 mg, 0.05 mmol) in EtOAc (20 mL) was 
stirred under H2 atmosphere (1 bar) at rt After 6 h, more Pd/C (1 mg) was added and 
hydrogenation was continued for 5 h. The black suspension was filtered over Hyflo. The filtrate 
was concentrated to obtain the product (44 mg, 67 %). 1H NMR (500 MHz, CDCl3) δ 8.12 (br s, 
1H), 8.03 (d, J = 7.7 Hz, 2H), 7.71 (s, 1H), 7.68 – 7.59 (m, 2H), 7.59 – 7.51 (m, 3H), 7.51 – 7.46 
(m, 1H), 7.43 (t, J = 7.4 Hz, 2H), 7.22 (d, J = 8.0 Hz, 1H), 7.19 – 7.08 (m, 2H), 6.87 (d, J = 7.4 
Hz, 1H), 3.67 (t, J = 6.3 Hz, 2H), 3.06 (t, J = 6.3 Hz, 2H), 2.24 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 170.6, 163.9, 159.2, 154.6, 138.9, 138.2, 137.8, 136.4, 130.7, 130.2, 129.2, 128.9, 
128.6, 127.8, 124.9, 120.3, 118.8, 116.7, 116.6, 106.2, 34.7, 32.0, 21.6, two carbon signals likely 
overlap. LCMS-purity 95%.  HRMS [M+H]+ calc: 418.1914, found: 418.1909. 
(E)-3-(3-cyano-4,6-diphenylpyridin-2-yl)-N-(m-tolyl)acrylamide (6, VUF14518) 
A mixture consisting of chloride 16 (192 mg, 0.66 mmol), acrylamide 18 (160 mg, 0.99 
mmol), NaOAc (65 mg, 0.79 mmol), nBu4NBr (234 mg, 0.73 mmol), (o-Tol)3P (40 mg, 0.13 
mmol) and Pd(OAc)2 (17 mg, 0.08 mmol) in DMF (20 mL) was stirred for 18 h at 145 °C. The 
green/brown suspension was diluted with satd. aq. NaHCO3-soln. The mixture was extracted 
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with EtOAc (2x20 mL). The combined organic layers were washed with water (3x20 mL) and 
brine (1x20 mL). The organic layer was dried (MgSO4), filtered and concentrated. The residue 
was purified by column chromatography (25% EtOAc in heptane) to give the product (173 mg, 
63%). 1H NMR (500 MHz, CD3OD) δ 8.36 – 8.29 (m, 2H), 8.17 (d, J = 14.8 Hz, 1H), 8.05 (s, 
1H), 7.85 (d, J = 14.8 Hz, 1H), 7.77 – 7.71 (m, 2H), 7.63 – 7.49 (m, 8H), 7.24 (t, J = 7.8 Hz, 
1H), 6.98 (d, J = 7.5 Hz, 1H), 2.36 (s, 3H). 13C NMR (126 MHz, CD3OD) δ 165.3, 160.8, 157.1, 
156.1, 140.0, 139.8, 138.7, 137.8, 136.6, 131.9, 131.8, 131.2, 130.1, 130.1, 129.8, 129.8, 128.8, 
126.4, 121.8, 121.5, 118.5, 117.1, 107.6, 21.6. LCMS- purity 98+ %. HRMS [M+H]+ calc: 
416.1763, found: 416.1762. 
3-((3-Cyano-4,6-diphenylpyridin-2-yl)thio)-N-(m-tolyl)propanamide (7, VUF14520) 
To a stirred solution of thiol 17d (200 mg, 1.02 mmol) in MeCN (10 mL) at 0 oC were added 
chloride 16 (298 mg, 1.02 mmol) and K2CO3 (142 mg, 1.02 mmol). The resulting mixture was 
stirred for 0.5 h at 0 oC and then 3 h at rt The mixture was concentrated under reduced pressure 
and purified by flash chromatography (gradient starting from 5% (1% Et3N/EtOAc) in heptane to 
80% (1% Et3N/EtOAc) in heptane). This afforded the product (160 mg, 35 %). 1H NMR (400 
MHz, CDCl3)  8.11 (dd, J = 6.4, 2.7 Hz, 2H), 7.66 – 7.58 (m, 2H), 7.58 – 7.44 (m, 7H), 7.31 (s, 
1H), 7.24 – 7.11 (m, 3H), 6.92 (d, J = 7.2 Hz, 1H), 3.79 (t, J = 7.2 Hz, 2H), 2.91 (t, J = 7.2 Hz, 
2H), 2.31 (s, 3H). 13C NMR (101 MHz, CDCl3)  169.1, 163.5, 158.9, 154.9, 139.1, 137.7, 
137.5, 136.3, 130.9, 130.3, 129.3, 129.2, 129.0, 128.5, 127.5, 125.4, 120.7, 117.1, 116.2, 115.7, 
104.3, 37.7, 26.5, 21.6. LCMS-purity: 98+ %. HRMS [M+H]+ calc: 450.1635, found: 450.1638. 
4-((3-Cyano-4,6-diphenylpyridin-2-yl)thio)-N-(m-tolyl)butanamide (8, VUF14523) 
To a stirred solution of thiol 17e (120 mg, 0.573 mmol) in MeCN (10 mL) at 0 oC were added 
chloride 16 (167 mg, 0.573 mmol) and K2CO3 (79 mg, 0.57 mmol). The resulting mixture was 
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stirred for 0.5 h at 0 oC and 3 h at rt The resulting mixture was concentrated under reduced 
pressure and purified by flash chromatography (gradient starting from 5% (1% Et3N/EtOAc) in 
heptane to 80% (1% Et3N/EtOAc) in heptane). This afforded the product (20 mg, 8 %). 1H NMR 
(400 MHz, CDCl3)  8.13 – 8.04 (m, 2H), 7.65 – 7.59 (m, 2H), 7.55 - 7.51 (m, 4H), 7.50 – 7.46 
(m, 3H), 7.36 (s, 1H), 7.26 – 7.12 (m, 3H), 6.90 (d, J = 7.2 Hz, 1H), 3.55 (t, J = 6.5 Hz, 2H), 
2.59 (t, J = 7.1 Hz, 2H), 2.38 – 2.25 (m, 5H). 13C NMR (101 MHz, CDCl3)  170.2, 163.5, 
158.7, 154.6, 138.9, 137.7, 137.3, 136.2, 130.6, 130.1, 129.1, 129.0, 128.8, 128.4, 127.4, 125.1, 
120.4, 116.8, 115.9, 115.9, 103.9, 36.0, 30.0, 24.8, 21.5. LCMS purity: 95+ %. HRMS [M+H]+ 
calc: 464.1791, found: 464.1785. 
2-(Methylthio)-4,6-diphenylnicotinonitrile (9, BAS-85) 
To a stirred solution of thiol 29 (144 mg, 0.499 mmol) in anhydrous DMF (6 mL) were added 
Cs2CO3 (163 mg, 0.500 mmol) and TBAI (185 mg, 0.501 mmol). The resulting mixture was 
stirred for 1 h at rt After cooling to 0 °C, MeI (0.106 g, 0.75 mmol) dissolved in DMF (0.3 mL) 
was introduced via syringe. The mixture was warmed to rt and stirred for an additional 2 h. After 
quenching with cold water (20 mL), the mixture was extracted with DCM (3 x 15 mL). The 
combined organic layers were dried over MgSO4, filtered and the solvents removed under 
vacuum. The residue was purified by column chromatography (n-hexane/Et2O 5/1) yielding the 
product as a white solid (51 mg, 34%). 1H NMR (600 MHz, CDCl3) δ 8.14-8.12 (m, 2H), 7.64-
7.63 (m, 2H), 7.55-7.51 (m, 7H), 2.79 (s, 3H). 13C NMR (600 MHz, CDCl3) δ 164.5, 158.4, 
154.3, 137.5, 136.3, 130.6, 130.0, 129.0, 129.0, 128.4, 127.4, 115.9, 115.5, 103.7, 13.7. LCMS-
purity: 97+ %. HRMS [M+H]+ calc: 303.0950, found: 303.0939. 
4,6-Diphenylnicotinonitrile (10, BAS-87) 
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PdCl2 (2.5 mg, 0.014 mmol) was added to a degassed suspension of chloride 16 (290 mg, 1.00 
mmol) and NaOAc (165 mg, 2.01 mmol) in MeOH (8 mL). The heterogeneous mixture was 
stirred under hydrogen (1 atm) at rt After 36 h, the suspension was filtered and the precipitate 
was carefully washed with methanol (2 x 5 mL) and DCM (3 x 10 mL). The combined organic 
filtrates were evaporated under reduced pressure and DCM (20 mL) was added to the residue. 
The resulting solution was filtered through a thin pad of silica gel, which was washed with an 
additional portion of DCM. After removal of the solvent under reduced pressure, the crude 
product was purified by column chromatography (n-hexane/Et2O 4/1), affording the target 
compound as white solid (97 mg, 38%). 1H NMR (600 MHz, CDCl3) δ 9.01 (s, 1H), 8.10-8.08 
(m, 2H), 7.88 (s, 1H), 7.69-7.67 (m, 2H,), 7.59-7.50 (m, 6H). 13C NMR (600 MHz, CDCl3) δ 
160.5, 154.0, 153.0, 137.5, 135.9, 130.6, 130.2, 129.2, 129.1, 128.4, 127.5, 120.4, 117.2, 106.6. 
LCMS-purity: 99+ %. HRMS [M+H]+ calc: 257.1073, found: 257.1073. 
2-((4,6-Diphenylpyridin-2-yl)thio)-N-(m-tolyl)acetamide (11, BAS-86) 
A glass tube was charged with chloride 25 (200 mg, 0.75 mmol), CuI (15 mg, 0.079 mmol), L-
proline (20 mg, 0.17 mmol) and K2CO3 (210 mg, 1.5 mmol). The tube was evacuated and filled 
with argon (3 cycles). Thiol 17a (0.150 g, 0.825 mmol) dissolved in anhydrous DME (2 mL) was 
introduced via syringe. The tube was sealed and heated under reflux for 30 h while stirring. After 
cooling to rt, the reaction mixture was partitioned between DCM (20 mL) and satd. aq. NaCl (10 
mL). The organic layer was separated and the aqueous layer was extracted with DCM (2 x 10 
mL). The combined organic layers were dried over MgSO4, filtered and the solvent removed 
under reduced pressure. The crude product was purified by column chromatography 
(DCM/MeOH 6/0.1), affording the target compound as white solid (65 mg, 21 %). 1H NMR (600 
MHz, CDCl3) δ 9.97 (br s, 1H, NH), 8.08-8.04 (m, 2H), 7.71 (d, 1H, J = 1.4 Hz), 7.68-7.64 (m, 
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2H), 7.55-7.48 (m, 6H), 7.44 (d, 1H, J = 1.4 Hz), 7.07-6.95 (m, 2H), 6.74 (d, 1H, J = 7 Hz), 6.62 
(s, 1H), 4.05 (s, 2H), 2.07 (s, 3H). 13C NMR (600 MHz, CDCl3) δ 168.1, 158.2, 158.0, 150.6, 
138.7, 138.4, 138.2, 137.6, 129.8, 129.6, 129.3, 129.2, 128.6, 127.2, 127.2, 124.4, 119.9, 118.6, 
116.4, 116.1, 35.1, 21.1. LCMS-purity: 99+ %. HRMS [M+H]+ calc: 411.1526, found: 411.1529. 
2-((3-Cyano-6-phenylpyridin-2-yl)thio)-N-(m-tolyl)acetamide (12, VUF14469) 
To a stirred solution of chloride 23a (0.100 g, 0.466 mmol) in MeCN (10 mL) at 0 oC in the 
dark were added thiol 17a (0.093 g, 0.51 mmol) and K2CO3 (0.097 g, 0.70 mmol). The resulting 
mixture was stirred for 0.5 h at rt and then concentrated. The crude product was purified by 
column chromatography (using a gradient starting from 15% (1% Et3N/EtOAc) in heptane to 
80% (1% Et3N/EtOAc) in heptane). This provided the product as a solid (17 mg, 10 %). Note: 
All of this work, including the column chromatography, has to be done in the dark as the 
compound is photolytically unstable (as proven by NMR and LCMS studies after exposing the 
compound to day light). 1H NMR (500 MHz, CDCl3)  7.67 (s, 1H), 7.58 – 7.45 (m, 3H), 7.35 (s, 
1H), 7.31 (d, J = 7.2 Hz, 2H), 7.28 – 7.20 (m, 3H), 6.98 (d, J = 7.3 Hz, 1H), 6.81 (d, J = 11.9 Hz, 
1H), 3.73 (s, 2H), 2.35 (s, 3H). 13C NMR (126 MHz, CDCl3)  163.7, 163.6, 155.2, 139.4, 136.9, 
134.2, 131.49, 129.5, 129.4, 129.2, 126.2, 120.9, 118.8, 117.3, 114.1, 112.2, 80.2, 37.9, 21.6. 
LCMS-purity: 95+ %. HRMS [M+H]+ calc: 360.1165, found: 360.1166. 
2-((3-Cyano-4-phenylpyridin-2-yl)thio)-N-(m-tolyl)acetamide (13, VUF14468) 
To a stirred mixture of chloride 23b (100 mg, 0.466 mmol) and NaOAc (57.3 mg, 0.699 
mmol) in MeCN (5 mL) was added thiol 17a (84 mg, 0.46 mmol). The mixture was stirred 
overnight at rt after which the temperature was raised to 40 oC. After 5 d, the solvent was 
evaporated and the remaining solids were subjected to extraction with DCM (40 mL) and water 
(2x20 mL) then brine (20 mL). The organic layer was dried (MgSO4), filtered and concentrated. 
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The crude product was purified by column chromatography (using a gradient from 1:9 
EtOAc:heptane to 5:5 EtOAc:heptane). This yielded the product as a solid (25 mg, 15 %). 1H 
NMR (400 MHz, CDCl3)  9.03 (br, 1H), 8.67 (d, J = 5.2 Hz, 1H), 7.63 – 7.50 (m, 5H), 7.36 (s, 
1H), 7.27 – 7.24 (m, 2H), 7.19 (t, J = 7.8 Hz, 1H), 6.92 (d, J = 7.4 Hz, 1H), 4.05 (s, 2H), 2.34 (s, 
3H). 13C NMR (101 MHz, CDCl3)  166.5, 162.9, 154.8, 151.3, 139.2, 137.8, 135.3, 130.7, 
129.4, 129.0, 128.6, 125.4, 120.8, 120.5, 116.9, 114.8, 106.5, 35.2, 21.7. LCMS-purity: 98+ %. 
HRMS [M+H]+ calc: 360.1165, found: 360.1167. 
2-((4,6-Diphenylpyrimidin-2-yl)thio)-N-(m-tolyl)acetamide (14, VUF14477) 
To a stirred solution of chloride 23c (150 mg, 0.562 mmol) in MeCN (10 mL) at 0 oC were 
added thiol 17a (112 mg, 0.619 mmol) and K2CO3 (117 mg, 0.844 mmol). The resulting mixture 
was stirred for 5 h while being allowed to warm to rt. The solvent was partially evaporated and 
the resulting mixture was filtered. The residue was dissolved in EtOAc and subjected to column 
chromatography (100% EtOAc). This yielded the product as a solid (120 mg, 52 % yield). 1H 
NMR (500 MHz, CDCl3)  9.28 (s, 1H), 8.14 – 8.06 (m, 4H), 7.81 (s, 1H), 7.56 – 7.46 (m, 6H), 
7.05 (d, J = 8.3 Hz, 1H), 6.98 (t, J = 7.8 Hz, 1H), 6.78 (s, 1H), 6.73 (d, J = 7.4 Hz, 1H), 4.00 (s, 
2H), 2.07 (s, 3H). 13C NMR (126 MHz, CDCl3)  171.1, 167.4 (split), 165.6, 138.6, 137.9 (split), 
136.3, 131.6, 129.2, 128.7, 127.4, 124.8 (split), 120.1 (split), 116.5 (split), 109.2, 35.9 (split), 
21.3, splitting of some peaks was observed. LCMS-purity: 99+%. HRMS [M+H]+ calc: 
412.1484, found: 412.1489. 
2-((4,6-Bis(4-trifluoromethyl)phenyl)pyrimidin-2-yl)thio)-N-(m-tolyl)acetamide (15, 
VUF14525) 
Thiol 17a (54 mg, 0.30 mmol) and K2CO3 (21 mg, 0.15 mmol) were added to a stirred solution 
of chloride 23d (40 mg, 0.099 mmol) in MeCN (10 mL) at 0 °C. The mixture was stirred for 2.5 
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h while being allowed to warm to rt. The solvent was partially evaporated and the resulting 
mixture was filtered. The residue was purified by column chromatography (heptane:EtOAc 4:1) 
to yield the compound as a white solid (20 mg, 37 %). 1H NMR (400 MHz, CDCl3)  8.79 (br s, 
1H), 8.26 (d, J = 8.2 Hz, 4H), 7.89 (s, 1H), 7.81 (d, J = 8.3 Hz, 4H), 7.18 (d, J = 8.2 Hz, 1H), 
7.09 (t, J = 7.8 Hz, 1H), 6.99 (s, 1H), 6.84 (d, J = 7.5 Hz, 1H), 4.05 (s, 2H), 2.18 (s, 3H). 13C 
NMR (101 MHz, CDCl3)  171.4, 166.6, 164.5, 139.3, 138.9, 137.5, 133.3 (q, 2J = 32.8 Hz), 
128.9, 127.9, 126.2 (q, 3J = 3.8 Hz), 125.2, 123.7 (q, 1J = 272.5 Hz), 120.2, 116.6, 109.6, 36.0, 
21.3. LCMS-purity: 95%. HRMS [M+H]+ calc: 548.1226, found: 548.1216. 
3-Mercapto-N-(m-tolyl)propanamide (17d) 
3-Mercaptopropanoic acid (1.06 g, 10.0 mmol) was combined with m-toluidine (1.093 mL, 
10.0 mmol). After 1 h of stirring at rt, the mixture was heated in the microwave for 1 h at 180 oC. 
The crude product was purified using column chromatography (25% EtOAc in heptane). This 
afforded the product (1.64 g, 84 %). 1H NMR (250 MHz, CDCl3)  7.39 (s, 1H), 7.32 (br s, 1H), 
7.28 (d, J = 8.1 Hz, 1H), 7.20 (t, J = 7.8 Hz, 1H), 6.94 (d, J = 7.5 Hz, 1H), 2.93 – 2.85 (m, 2H), 
2.67 (t, J = 6.6 Hz, 2H), 2.33 (s, 3H), 1.70 (t, J = 8.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
169.2, 139.3, 137.7, 129.1, 125.6, 120.8, 117.2, 41.6, 21.7, 20.6. LCMS purity: 95+ %. 
4-Mercapto-N-(m-tolyl)butanamide (17e) 
Dihydrothiophen-2(3H)-one (0.866 mL, 10.0 mmol) was mixed with m-toluidine (1.09 mL, 
10.0 mmol) at -5 oC. The mixture was heated in the microwave (3 h at 120 oC, then 1 h at 160 oC 
and finally 24 h at 180 oC), resulting in partial conversion. The mixture was purified using 
column chromatography (25% EtOAc in heptane). This afforded the product (375 mg, 18 %). 1H 
NMR (500 MHz, CDCl3)  7.38 (s, 1H), 7.29 – 7.26 (m, 1H), 7.20 (t, J = 7.8 Hz, 1H), 7.16 (br s, 
1H), 6.93 (d, J = 7.4 Hz, 1H), 2.70 – 2.60 (m, 2H), 2.51 (t, J = 7.2 Hz, 2H), 2.34 (s, 3H), 2.04 (p, 
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J = 7.0 Hz, 2H), 1.36 (t, J = 8.0 Hz, 1H). 13C NMR (126 MHz, CDCl3)  170.4, 139.2, 137.8, 
129.0, 125.3, 120.6, 117.0, 35.8, 29.3, 24.2, 21.6. LCMS purity: 95+ %. 
N-(m-tolyl)acrylamide (18) 
Acryloyl chloride (0.41 mL, 5.3 mmol) was added to a stirred solution of m-toluidine (0.54 
mL, 5.0 mmol) and Et3N (0.89 mL, 6.4 mmol) in THF (10 mL) at 0 °C. The orange suspension 
was stirred for 2.5 h and poured onto brine (10 mL). The mixture was extracted with tBuOMe 
(2x). The organic layers were dried over Na2SO4, filtered and concentrated. The crude product 
was purified by column chromatography (25% EtOAc in heptane) to obtain the product as a 
transparent oil (0.57 g, 70 %). 1H NMR (250 MHz, CDCl3) δ 7.45 (s, 1H), 7.38 – 7.29 (m, 1H), 
7.30 (br, 1H), 7.20 (t, J = 7.9 Hz, 1H), 6.95 (d, J = 7.4 Hz, 1H), 6.43 (dd, J = 16.8, 1.3 Hz, 1H), 
6.24 (dd, J = 16.8, 10.1 Hz, 1H), 5.76 (dd, J = 10.0, 1.4 Hz, 1H), 2.34 (s, 3H). LCMS-purity: 
97%. 
2-Chloro-4,6-diphenylpyrimidine (23c) 
Prepared according to a published procedure.49 1H NMR (500 MHz, CDCl3) δ 8.19 – 8.12 (m, 
4H), 8.02 (s, 1H), 7.59 – 7.48 (m, 6H).13C NMR (126 MHz, CDCl3) δ 167.7, 162.1, 135.7, 131.7, 
129.1, 127.5, 111.0. LCMS-purity: 95+ %. 
2-Chloro-4,6-bis(4-(trifluoromethyl)phenyl)pyrimidine (23d) 
2,4,6-Trichloropyrimidine (92 mg, 0.50 mmol), 4-(trifluoromethyl)phenylboronic acid (190 
mg, 1.00 mmol) and K2CO3 (428 mg, 3.10 mmol, dissolved in a minimum amount of H2O) were 
mixed with 1,2-dimethoxyethane (10 mL). The flask was covered with aluminium foil. Pd(OAc)2 
(3 mg, 0.01 mmol) and PPh3 (7 mg, 0.03 mmol) were added to the mixture. The mixture was 
heated at 60 °C for 24 h. The solvent was removed by rotary evaporation and the residue 
subjected to extraction with DCM and H2O. The organic layer was washed three times with H2O, 
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dried over Na2SO4, filtered and concentrated. The residue was purified by three successive 
column chromatography operations (heptane:EtOAc 6:1, then PhMe:MeCOMe 8:1, then 
PhMe:heptane 4:1). This yielded the product as a clear oil which slowly crystallized (40 mg, 20 
%). 1H NMR (250 MHz, CDCl3) δ 8.28 (d, J = 8.1 Hz, 4H), 8.08 (s, 1H), 7.82 (d, J = 8.3 Hz, 
4H). LCMS-purity: 95%. 
2-Chloro-4,6-diphenylpyridine (25) 
A mixture of pyridone 24 (370 mg, 1.50 mmol) and POCl3 (3.0 mL) was heated under reflux 
for 4 d. After cooling to rt the crude product was poured onto crushed ice. The mixture was 
neutralized with cold 15 % aq. KOH and the precipitate was collected by filtration, washed with 
water and dissolved in DCM. The resulting solution was washed once more with diluted KOH 
and water. After drying the organic layer over MgSO4 and filtration, the solvent was removed 
under reduced pressure. The crude product was purified by column chromatography (DCM) 
yielding the target compound as white solid (213 mg, 53%). 1H NMR (600 MHz, CDCl3) δ 8.02-
7.98 (m, 2H), 7.63 (s, 1H), 7.51-7.43 (m, 9H). 
2-Chloro-1-morpholinoethan-1-one (28) 
To a stirred solution of morpholine (435 mg, 4.99 mmol) in anhydrous THF (14 mL), K2CO3 
(1.88 g, 10 mmol) was introduced. The reaction mixture was cooled to 0 °C and ClCH2COCl 
(678 mg, 6.00 mmol) dissolved in THF (3 mL) was added drop wise. The reaction was warmed 
to rt and stirred for 1 h. After filtration, the filtrate was evaporated affording the target compound 
as a viscous oil with 95% purity according to 1H NMR spectroscopy (620 mg, 76%). 1H NMR 
(600 MHz, CDCl3) δ 4.08 (s, 2H), 3.78-3.72 (m, 4H), 3.66-3.62 (m, 2H), 3.56-3.52 (m, 2H). 
Biological assays.  
Compounds and PB1 peptide.  
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RBV (1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) and oseltamivir carboxylic acid, the 
active form of oseltamivir [(3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-
1-carboxylic acid] were purchased from Roche. Test compounds were dissolved in dimethyl 
sulfoxide (DMSO). Since photochemical degradation of compound 12 under daylight conditions 
was observed during compound synthesis, all solutions containing 12 were protected from 
daylight and all experiments with this compound were performed in the dark. The PB1(1–15)–Tat 
peptide was synthesized and purified by the Peptide Facility of CRIBI Biotechnology Center 
(University of Padua, Italy). This peptide contains the first 15 N-terminal amino acids of PB1 
protein fused to the C-terminal sequence of HIV Tat protein (amino acids 47−59). 
Plasmids. 
Plasmids pcDNA−PB1, pcDNA−PB2, pcDNA−PA, and pcDNA−NP, containing cDNA copies 
of the influenza A/PR/8/34 virus PB1, PB2, PA, and NP genes, respectively, were created as 
described elsewhere52 and kindly provided by P. Digard (Roslin Institute, University of 
Edinburgh, United Kingdom). Plasmid pPolI−Flu−ffLuc, which contains an influenza virus-
based luciferase minireplicon vRNA under the control of the human RNA polymerase I 
promoter, was provided by L. Tiley (University of Cambridge, United Kingdom). Plasmid 
pRL−SV40 expressing the Renilla luciferase, was purchased from Promega. 
Cells and Virus. 
Human embryonic kidney 293T (HEK 293T) and MDCK cells were cultivated in Dulbecco’s 
modified Eagle’s medium (DMEM, Life Biotechnologies) supplemented with 10% (v/v) fetal 
bovine serum (FBS, Life Technologies) and antibiotics (100 U/mL penicillin and 100 μg/mL 
streptomycin, Life Technologies). The cells were maintained at 37 °C in a 5% CO2 humidified 
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atmosphere. Influenza A/PR/8/34 virus (PR8 strain, H1N1, Cambridge lineage) was obtained 
from P. Digard (Roslin Institute, University of Edinburgh, United Kingdom).  
PA−PB1 Interaction Enzyme-Linked Immunosorbent Assay (ELISA). 
The PA−PB1 interaction was detected as described by Muratore et al.,29 with some 
modifications. Briefly, microtiter plates (Nuova Aptca) were incubated with 400 ng of 6His-
PA(239−716) for 3 h at 37 °C and then blocked with 2% BSA (Sigma) in PBS for 1 h at 37 °C. 
After washing, 200 ng of GST-PB1(1−25) dissolved in PBS, or GST as a control, in the presence 
of test compounds at various concentrations or DMSO, were added and incubated overnight at 
room temperature. E. coli-expressed, purified 6His-PA(239−716), GST and GST-PB1(1−25) proteins 
were obtained as previously described.29,53 After washing, the interaction between 
6His−PA(239−716) and GST−PB1(1−25) was detected with an anti-GST monoclonal antibody 
conjugated to horseradish peroxidase (HRP) (Gen-Script). After the final wash step, the substrate 
3,3′,5,5′-tetramethylbenzidine (TMB, KPL) was added, and the optical density was determined at  
450 nm by an ELISA plate reader (Tecan Sunrise). Values obtained from the samples treated 
with only DMSO were used to set as 100% of PA−PB1 interaction. The PB1(1−15)−Tat peptide 
was included in all experiments as the reference inhibitor. 
In the modified PA−PB1 interaction ELISA, the assay was performed as described above, 
except that GST-PB1(1−25), or GST as a control, along with test compounds at various 
concentrations or DMSO were dissolved in serum-free DMEM instead of PBS. The 
PB1(1−15)−Tat peptide was included in all experiments as a positive control for inhibition. 
Plaque Reduction Assay (PRA). 
A confluent monolayer of MDCK cells was prepared in 12-well plates. Cells were infected 
with FluA virus (PR8 strain) at 40 PFU/well in DMEM supplemented with 1 µg/ml of TPCK-
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treated trypsin (Worthington Biochemical Corporation) and 0.14% BSA in the presence of 
various concentrations of test compounds for 1 h at 37 °C. Medium containing 1 µg/ml of 
TPCK-treated trypsin, 0.14% BSA, 1.2% Avicel, and test compounds at the same concentrations 
was then added. After 2 days of incubation, cell monolayers were fixed with 4% formaldehyde 
and stained with 0.1% toluidine blue, and viral plaques were counted. Ribavirin and Oseltamivir 
were included in all experiments as the reference compound. 
Cytotoxicity Assay. 
Cytotoxicity of test compounds was assessed in MDCK and HEK 293T cells by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, as previously reported.53 
Briefly, MDCK cells (5x103 cells/well on 96-well plates) and HEK 293T (2x104 cells/well on 96-
well plates) cells were incubated with compound at 2-fold serial dilutions from 250 µM. After 24 
or 48 h for HEK 293T and MDCK cells, respectively, MTT solution (5 mg/mL in PBS) was 
added to each well and plates were incubated for 4 h at 37 °C. Then, a solubilisation solution was 
added to lyse cells. After 3 h of further incubation at 37°C, absorbance was read at 620 nm using 
an ELISA plate reader (Tecan Sunrise). Values obtained from the wells treated with only DMSO 
were used to set as 100% of viable cells. 
Minireplicon Assay. 
HEK 293T cells were seeded at a density of 2x105 per well into 24-well plates. After 24 h, 
cells were transfected with pcDNA-PB1, pcDNA-PB2, pcDNA-PA, pcDNA-NP plasmids (100 
ng/well of each) along with pPolI-Flu-ffLuc plasmid (50 ng/well). The transfection mixture also 
contained pRL-SV40 plasmid (50 ng/well) to normalize variations in transfection efficiency. 
Transfections were performed using calcium phosphate protocol in the presence of the test 
compounds or DMSO. Cell medium was replaced 4 h post-transfection with DMEM containing 
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compounds or DMSO. At 24 h post-transfection, cells were harvested and both firefly luciferase 
and Renilla luciferase expression were determined using the Dual Luciferase Assay Kit from 
Promega. Ribavirin was included in all experiments as the reference compound. 
Interference Compounds assessment. 
The structure of all tested compounds (1-15) was examined for known classes of assay 
interference compounds with the online FAF-Drug3 (Free ADME-Tox Filtering Tool) program.54 
Almost all the compounds passed the Pan Assay Interference Compounds (PAINS)55 filter, 
increasing the confidence in the presented results. Only compound 6 failed to pass the PAINS filter. 
However, since this molecule did not display good activity in any of the performed in vitro assays, no 
further investigations were performed. 
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